Page 19 - Anemia Hemolitica No autoinmune

Total HS patients
HS with biochemical defect Spectrin
Band3
Combined spectrin/ankyrin
HS with undetectable defect
B
140/150 (93%)
132/141 (94%) 68/73 (93%) 55/59 (93%)
92/150 (61%)
90/141 (64%) 45/73 (61%) 38/59 (64%)
7/9 (78%)
2/9 (22%)
143/150 (95%)
135/141 (96%) 70/73 (96%) 56/59 (93%)
9/9 (100%)
8/9 (88%)
136/150 (91%)
131/141 (93%) 67/73 (92%) 55/59 (93%)
9/9 (100%)
2/9 (22%)
102/150 (68%)
100/141 (71%) 51/73 (70%) 43/59 (73%)
6/9 (67%)
3/9 (33%)
EMA + Pink
149/150 (99%)
Splenectomized
122/150 (81%)
119/141 (84%) 62/73 (85%) 49/59 (83%)
8/9 (89%)
4/9 (44%)
OF (NaCl inc.) + AGLT
146/150 (97%)
EMA + AGLT
EMA + OF (NaCl fresh)
143/150 (95%)
EMA + OF (NaCl inc.)
143/150 (95%)
9/9
8/9
(100%)
(88%)
Total HS patients 150/150 (100%)
OF: osmotic fragility; Inc.: incubated.
100
90
80
70
60
50
40
30
20
Not splenectomized
Severe-moderate Mild Compensated
Figure 1. Sensitivity of various diagnos- tic tests in 22 splenectomized and 128
Sensitivity %
10
not splenectomized patients with hered-